DURHAM, N.C., June 11, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that Jeff Abbey, president and chief executive officer, will be presenting at the 2014 Wells Fargo Healthcare Conference on June 17, 2014, at 4:40 p.m. Eastern Time at The InterContinental Hotel in Boston, MA. Mr. Abbey will also participate in a fireside chat at the JMP Securities 2014 Healthcare Conference on June 25, 2014 at 2:30 p.m. Eastern Time at The Westin New York Grand Central Hotel, in New York, NY.
The live audio webcasts of the presentations can be accessed via the Investors section of the Company's website at www.argostherapeutics.com. Please log in approximately 5-10 minutes before each event to ensure a timely connection. Replays of the webcasts will be available for 14 days following each presentation.
About Argos Therapeutics
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The company is also developing AGS-004, a personalized immunotherapy for the treatment of HIV, and expects to report data from a Phase 2b trial in mid-2014. For more information about Argos Therapeutics, visit www.argostherapeutics.com.